Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jules A A C Heuberger

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Sports Medicine (Auckland, N.Z.)|November 10, 2018
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing EffectsJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|July 22, 2021
Dealing with doping. A plea for better science, governance and educationJules A A C Heuberger, April Henning, Adam F Cohen, et al.
British Journal of Clinical Pharmacology|May 4, 2018
Futility of current urine salbutamol doping controlJules A A C Heuberger, Sven C van Dijkman, Adam F Cohen
International Journal of Molecular Sciences|February 10, 2021
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative DisordersMaurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld
British Journal of Clinical Pharmacology|May 15, 2025
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approachJules A A C Heuberger, Perry de Jongh, Ewoud-Jan van Hoogdalem, et al.
Clinical Pharmacokinetics|May 6, 2016
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy VolunteersEsther Peters, Jules A A C Heuberger, Renger Tiessen, et al.
Clinical and Translational Science|October 25, 2022
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over studyTitia Q Ruijs, Ingrid W Koopmans, Marieke L de Kam, et al.
Plos One|November 15, 2018
Repeatability and predictive value of lactate threshold concepts in endurance sportsJules A A C Heuberger, Pim Gal, Frederik E Stuurman, et al.
Physiological Reports|December 29, 2018
Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclistsWillem A J Birkhoff, Jules A A C Heuberger, Titiaan E Post, et al.
Clinical and Translational Science|May 13, 2023
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controlsMaurits F J M Vissers, Matthew D Troyer, Eva Thijssen, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Sports Medicine (Auckland, N.Z.)|November 10, 2018
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing EffectsJules A A C Heuberger, Adam F Cohen
British Journal of Clinical Pharmacology|July 22, 2021
Dealing with doping. A plea for better science, governance and educationJules A A C Heuberger, April Henning, Adam F Cohen, et al.
British Journal of Clinical Pharmacology|May 4, 2018
Futility of current urine salbutamol doping controlJules A A C Heuberger, Sven C van Dijkman, Adam F Cohen
International Journal of Molecular Sciences|February 10, 2021
Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative DisordersMaurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld
British Journal of Clinical Pharmacology|May 15, 2025
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approachJules A A C Heuberger, Perry de Jongh, Ewoud-Jan van Hoogdalem, et al.
Clinical Pharmacokinetics|May 6, 2016
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy VolunteersEsther Peters, Jules A A C Heuberger, Renger Tiessen, et al.
Clinical and Translational Science|October 25, 2022
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over studyTitia Q Ruijs, Ingrid W Koopmans, Marieke L de Kam, et al.
Plos One|November 15, 2018
Repeatability and predictive value of lactate threshold concepts in endurance sportsJules A A C Heuberger, Pim Gal, Frederik E Stuurman, et al.
Physiological Reports|December 29, 2018
Recombinant human erythropoietin does not affect several microvascular parameters in well-trained cyclistsWillem A J Birkhoff, Jules A A C Heuberger, Titiaan E Post, et al.
Clinical and Translational Science|May 13, 2023
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controlsMaurits F J M Vissers, Matthew D Troyer, Eva Thijssen, et al.
Pageof 4